Indeed, so far, several ICI (i.e., anti-cytotoxic T lymphocyte antigen-4 (CTLA-4), anti-programmed cell death protein-1 [PD-1], and anti-programmed death-ligand 1 (PD-L1)) have been approved for advanced RCC patients either as monotherapy or combined regimen [17,18]. This evidence concerns the gene PDCD1 and renal cell adenocarcinoma.